CN112791038A

CN112791038A - Cosmetic composition for anti-allergy repair and preparation method thereof

Info

Publication number: CN112791038A
Application number: CN202110239080.6A
Authority: CN
Inventors: 王璞
Original assignee: Shanghai Youren Biotechnology Co ltd
Current assignee: Shanghai Youren Biotechnology Co ltd
Priority date: 2020-03-05
Filing date: 2021-03-04
Publication date: 2021-05-14
Also published as: CN112791037A; CN111265458A

Abstract

The invention provides a cosmetic composition for anti-allergy repair and a preparation method thereof. The cosmetic has the synergistic anti-allergy effect through reasonable compatibility of the tetrandrine, the beta-sitosterol and the radix ophiopogonis extract, and in addition, the preparation method of the cosmetic composition is simple and can be produced and applied on a large scale. The cosmetic prepared by the application can be mild and anti-allergic, is suitable for people who are allergic and can relieve allergic symptoms. The onset of action is rapid and the TEWL value begins to decrease the following day of use. The barrier damage caused by improper nursing can accelerate the self-repairing process of the skin. Mainly comprises plant extracts, is mild and does not cause dependence.

Description

Cosmetic composition for anti-allergy repair and preparation method thereof

Technical Field

The invention relates to the field of cosmetics, in particular to a cosmetic for anti-allergy repair.

Background

The appearance of skin sensitivity is manifested by facial telangiectasia, flushing associated with vascular responses, and light-sensitive and contact dermatitis, among others. After the Kamstege team researches different skin sensitive people (such as allergic dermatitis, contact dermatitis, psoriasis and the like) through clinical experiments, the Kamstege team discovers that the expression levels of CAII, NELL2 and inflammatory factor interleukin-8 (IL-8) in the skin of patients with allergic dermatitis are obviously increased^l. Further studies have shown that Th2 cells play an important role in skin allergy, wherein inflammatory factors interleukin-4 (IL-4) and interleukin-13 (IL-13) are the major cytokines secreted by Th2 cells and are also important markers of Th2 cells, which can affect the differentiation of skin keratinocytes and the water retention and barrier functions, resulting in the appearance of skin allergy symptoms²-3. The results of in vitro cell experiments show that the combination of IL-4 and IL-13 or other inflammatory factors is used for stimulating human skin keratinocytes, the expression of genes CAII, NELL2 and IL-8 which are related to Th2 cell activation can be obviously improved, so that the skin keratinocytes can show symptoms of Atopic Dermatitis (Atopic Dermatitis) in vitro, and the phenotype is consistent with clinical findings⁴。

l.Kamsteeg,M.；Jansen,P.A.；van Vlijmen-Willems,I.M.；van Erp,P.E.；Rodi jk-0lthuis,D.；van der Valk,P.G.；Feuth,T.；Zeeuwen,P.L.；Schalkwi jk,J.,Molecular diagnostics of psoriasis,atopic dermatitis,allergic contact dermatitis and irritant cotact dermatitis.Br J Dermatol 2010,162(3),568-78.

2.Bernard,F.X.；Morel,F.；Camus,M.；Pedretti,N.；Barrault,C.；Garnier,J.；Lecron,J.C.,Keratinocytes under Fire of Proinflammatory Cytokines:Bona Fide Innate Immune Cells Involved in the Physiopathology of Chronic Atopic Dermatitis and Psoriasis.J Allergy(Cairo)2012,2012,718725.

3.Bogiatzi,S.I.；Fernandez,I.；Bichet,J.C.；Marloie-Provost,M.A.；Volpe,E.；Sastre,X.；Soumelis,V.,Cutting Edge:Proinflammatory and Th2 cytokines synergize to induce thymic stromal lymphopoietin production by human skin keratinocytes.J Immunol 2007,178(6),3373-7.

4.Lee,S.H.；Bae,I.H.；Choi,H.；Choi,H.W.；Oh,S.；Marinho,P.A.；Min,D.J.；Kim,D.Y.；Lee,T.R.；Lee,C.S.；Lee,J.,Ameliorating effect of dipotassium glycyrrhizinate on an IL-4-and IL-13-induced atopic dermatitis-like skin equivalent model.Arch Dermatol Res 2019,311(2),131-140.

The water content and TEWL in the skin are important indexes for researching the barrier function of the skin, and the lower the TEWL value of the skin is, the better the barrier function of the skin is, otherwise, the worse the barrier function of the skin is; the water content in the healthy stratum corneum should be kept between 10-30%. The skin barrier is compromised and the TEWL value increases significantly over a short period of time, while the water content in the skin decreases significantly over the same period of time. Thus, examining the skin for the same period of time for TEWL values and skin moisture content, the health of the skin barrier can be demonstrated.

Aiming at the problem of skin sensitivity, the anti-sensitivity cosmetics in the prior art have the following defects:

1. the irritation is large, and people who are allergic cannot use the product;

2. the onset of action is slow, mostly the prevention is the main, and the effect on skin suffering from allergy is slight;

3. for skin barrier damage caused by improper nursing, the skin can only be statically repaired, and the required period is long;

therefore, there is a need to develop a cosmetic effective against skin sensitivity and accelerating the repair of damaged skin.

Disclosure of Invention

In order to solve the above problems of the anti-allergy cosmetics in the prior art, the first aspect of the present invention provides a cosmetic composition for anti-allergy repair, comprising the following raw materials in parts by mass: 1-5 parts of tetrandrine, 5-10 parts of beta-sitosterol, 8-12 parts of radix ophiopogonis extract and auxiliary materials. Preferably, water is also included according to actual needs.

Further, the auxiliary materials are selected from any one or more than two of an emulsifier, a thickening agent, an antioxidant, a humectant, an emollient, an anti-inflammatory agent, a solubilizer, a chelating agent, an essence, a pH regulator, a preservative, a penetration enhancer, a skin feel regulator, a surfactant, a pigment and a propellant.

Further, the adjuvant is selected from one or more of cetearyl olive oleate, sorbitan olive oleate, cyclopentadimethylsiloxane, squalane, lecithin, hydrogenated lecithin, cetearyl alcohol, polydimethylsiloxane, tocopherol, jojoba (SIMMONDSIA CHINENSIS) seed oil, glycerol, carbomer, 1, 2-hexanediol, 1, 2-pentanediol, isoprene glycol, disodium EDTA, panthenol, menthol lactate, and sodium hyaluronate.

Further, the content of cetearyl olive oleate is 2-5%, the content of sorbitan olive oleate is 1-3%, the content of cyclopentadimethylsiloxane is 3-5%, the content of squalane is 5-8%, the content of lecithin is 1-2%, the content of hydrogenated lecithin is 0.05-1%, the content of cetearyl alcohol is 1-3%, the content of polydimethylsiloxane is 2-5%, the content of tocopherol is 0.05-1%, the content of jojoba (SIMMONDSIA CHINENSIS) seed oil is 1-5%, the content of glycerol is 3-8%, the content of carbomer is 0.05-0.5%, the content of 1, 2-hexanediol is 0.5-2%, the content of 1, 2-pentanediol is 0.5-5%, the content of isoprene glycol is 1-5%, the content of isoprene glycol is 1-5%, and the content of methyl glycol is 3-5%, The content of EDTA disodium is 0.05-0.2%, the content of panthenol is 0.5-5%, the content of menthol lactate is 0.05-0.5%, and the content of sodium hyaluronate is 0.02-0.2%.

Further, the preparation method of the radix ophiopogonis extract comprises the following steps: pulverizing radix Ophiopogonis, mixing radix Ophiopogonis and water at a mass ratio of 1:8, heating to 80-100 deg.C, extracting for 2-4 hr, and concentrating under reduced pressure to 0.4 vol to obtain radix Ophiopogonis extract.

Further, the cosmetic composition is in the form of cream, lotion, gel, aerosol or aqua.

Further, the cosmetic is selected from one or more of facial mask, face cleaning lotion, skin care water, skin care lotion, skin care cream, skin care gel, skin care spray and foundation liquid.

A second aspect of the present application provides a method for preparing a cosmetic composition for anti-allergy restoration, comprising the steps of:

the method comprises the following steps: mixing the oil phase components uniformly, heating to 70-80 ℃, and stirring at 500rpm until no particles exist;

step two: uniformly mixing the water phase components, heating to 70-80 ℃, and stirring at 500rpm until no particles exist;

step three: adding the oil phase component into the water phase component, stirring at 45rpm, homogenizing at 3000rpm, and homogenizing for 5-10 min;

step four: stirring the oil phase component and the water phase component together until the components are uniform and have no particles, and then preserving the heat at 70-80 ℃ for 30 minutes;

step five: after the heat preservation time is up, cooling to 35 ℃, sequentially adding active phase components, wherein the addition time interval between each active phase component is 2 minutes;

step six: after the active phase is added, stirring for 10-30 minutes until the active phase is uniform and has no particles;

step seven: detecting viscosity, density, PH, appearance and microorganism, specifically, viscosity, density and PH, discharging after the appearance detection is qualified, and filling and packaging after the microorganism detection is qualified;

wherein the oil phase component comprises 2-5% cetearyl olive oleate, 1-3% sorbitan olive oleate, 3-5% cyclopentadimethylsiloxane, 5-8% squalane, 1-2% lecithin, 0.05-1% hydrogenated lecithin, 1-3% cetearyl alcohol, 2-5% polydimethylsiloxane, 0.05-1% tocopherol, and 1-5% jojoba (SIMMONDSIA CHINENSIS) seed oil;

wherein the water phase component comprises 3-8% of glycerin, 0.05-0.5% of carbomer, 0.5-2% of 1, 2-hexanediol, 0.5-5% of 1, 2-pentanediol, 1-5% of isoprene glycol, 0.05-0.2% of EDTA disodium, 0.5-5% of panthenol, 0.05-0.5% of menthol lactate, 0.02-0.2% of sodium hyaluronate and the balance of water;

the active phase comprises the following raw materials in parts by mass: 1-5 parts of tetrandrine, 5-10 parts of beta-sitosterol and 8-12 parts of radix ophiopogonis extract. Preferably, the active phase components comprise 0.0001-0.0005% of Stephania tetrandra extract, 0.0005-0.001% of beta-sitosterol and 0.0008-0.0012% of Ophiopogon japonicus root extract.

All reagents and starting materials are commercially available in this application unless otherwise specified.

Unless otherwise specified, the content unit "%" of each component in the present application means mass percent.

By adopting the technical scheme, compared with the prior art, the invention has the following technical effects:

the cosmetic composition for anti-allergy restoration provided by the invention has the synergistic anti-allergy effect through reasonable compatibility of the tetrandrine, the beta-sitosterol and the radix ophiopogonis extract, and in addition, the preparation method of the cosmetic composition is simple, and the cosmetic composition can be produced and applied on a large scale.

The cosmetic for anti-allergy restoration obtained by the preparation method has the following advantages:

1. is mild and anti-allergic, is suitable for people suffering from allergy, and can relieve allergy symptoms.

2. The quick-acting skin cream has the advantages that the TEWL value begins to decrease on the next day of use, and the moisture content of the skin begins to increase.

3. The barrier damage caused by improper nursing can accelerate the self-repairing process of the skin.

4. Mainly comprises plant extracts, is mild and does not cause dependence.

Drawings

FIG. 1 is a bar graph of the effect of different concentrations of ophiopogon root extract, tetrandrine and beta-sitosterol on the viability of human primary skin keratinocytes;

FIG. 2 is a bar graph of the effect of tetrandrine/β -sitosterol complex, radix Ophiopogonis extract, and the compatibility of the complex and radix Ophiopogonis extract on Th2 activation-related gene CAII in a validation example of the present invention;

FIG. 3 is a bar graph of the effect of tetrandrine/β -sitosterol complex, radix Ophiopogonis extract, and the compatibility of the complex and radix Ophiopogonis extract on Th2 activation-related gene NELL2 in a validated embodiment of the invention;

FIG. 4 is a bar graph of the effects of tetrandrine/β -sitosterol complex, radix Ophiopogonis extract, and the compatibility of the complex and radix Ophiopogonis extract on the expression of IL-8 in a validation example of the present invention;

FIG. 5 is a bar graph of the effect of tetrandrine/β -sitosterol complex, radix Ophiopogonis extract, and the compatibility of the complex and radix Ophiopogonis extract on the Th2 activation-related gene CAII in a validation example of the present invention;

FIG. 6 is a bar graph of the effect of tetrandrine/β -sitosterol complex, radix Ophiopogonis extract, and the compatibility of the complex and radix Ophiopogonis extract on Th2 activation-related gene NELL2 in a validated embodiment of the invention;

FIG. 7 is a bar graph of the effects of tetrandrine/β -sitosterol complex, radix Ophiopogonis extract, and the compatibility of the complex and radix Ophiopogonis extract on the expression of IL-8 in a validation example of the present invention;

FIG. 8 is a bar graph of the effect of tetrandrine/β -sitosterol complex, radix Ophiopogonis extract, and the compatibility of the complex and radix Ophiopogonis extract on the Th2 activation-related gene CAII in a validation example of the present invention;

FIG. 9 is a bar graph of the effect of tetrandrine/β -sitosterol complex, radix Ophiopogonis extract, and the compatibility of the complex and radix Ophiopogonis extract on Th2 activation-related gene NELL2 in a validated embodiment of the invention;

FIG. 10 is a bar graph of the effects of tetrandrine/β -sitosterol complex, radix Ophiopogonis extract, and the compatibility of the complex and radix Ophiopogonis extract on the expression of IL-8 in a validation example of the present invention;

FIG. 11 is a graph of the change in TEWL values for skin with compromised barrier after application of different groups of compositions;

fig. 12 is a graph of the change in skin moisture content for skin with compromised barrier after application of different groups of compositions.

Detailed Description

The advantages of the invention are further illustrated in the following description of specific embodiments in conjunction with the accompanying drawings. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and is not to be taken as limiting the scope of the invention.

Cell viability assay:

materials and reagents: human primary skin keratinocytes, beta-sitosterol, tetrandrine, radix ophiopogonis extract, a keratinocyte culture medium, an ELISA kit and a CCK-8 kit.

The main equipment is as follows: a cell culture box, a real-time fluorescence quantitative PCR instrument, an ultra-clean workbench and a microplate reader (Tecan).

Preparation of samples in advance: the following validation examples tested a total of 3 samples, the specific information of which is shown in table 1 below. In the efficacy evaluation experiment, the efficacy of the single medicine and the composition with different concentrations of each sample needs to be set for comparison, so the samples need to be respectively stored. DMSO accounts for a very low concentration in the experiment, and has no influence on the experimental result. Table 1 is used to describe the physicochemical properties and preservation of the samples tested, and is of reference significance for the subsequent preparation of the cell experimental samples.

Table 1 test sample information

Sample name	Physical and chemical properties	Sample preparation	Storage conditions
				Beta-sitosterol	Powder of	After DMSO is dissolved, subpackaging and freezing	-20℃
Tetrandrine	Powder of	After DMSO is dissolved, subpackaging and freezing	-20℃
				Radix Ophiopogonis extract	Liquid, method for producing the same and use thereof	Dilution and filtration of culture medium	-20℃

The cell viability is tested, comprising the following steps:

human primary skin keratinocytes were cultured in a medium containing 5% CO at 37 deg.C₂And culturing in an incubator with the humidity of 95 percent. After the cells grow to be fused with more than 80%, the cells are planted in a 96-well plate, beta-sitosterol or tetrandrine or radix ophiopogonis extract with different concentrations is added into each well for culturing for 96h, and the cell activity is detected by a CCK kit. The results are shown in FIG. 1.

And (3) analyzing test results: as can be seen from fig. l, tetrandrine has no toxic effect on human primary skin keratinocytes when the mass percentage of tetrandrine is 0.0006% or less, β -sitosterol has no toxic effect on human primary skin keratinocytes when the mass percentage of β -sitosterol is 0.00004% to 0.002%, and the ophiopogon root extract having a mass percentage concentration of 0.01% or less has no significant toxic effect on cells, so that the cell viability is not significantly affected, and the lower the concentration of the ophiopogon root extract, the lower the toxicity is.

In each of the examples and the verification examples described below, 1 part by mass was set to 0.0001 wt%.

Example 1

The composite active matter of the embodiment comprises the following raw materials in parts by mass: 3 parts of tetrandrine, 8 parts of beta-sitosterol and 10 parts of radix ophiopogonis extract. The preparation method of the radix ophiopogonis extract comprises the following steps: pulverizing radix Ophiopogonis, mixing radix Ophiopogonis and water at a mass ratio of l to 8, heating to 90 deg.C, extracting for 3 hr, decolorizing with active carbon, and concentrating under reduced pressure to 0.4 volume to obtain radix Ophiopogonis extract.

Effect example 1: the effect of the composition prepared in example 1 on the expression levels of Th 2-associated genes (CAII gene and NELL2 gene) and inflammatory factor (IL-8) was examined

The detection of the expression level of the Th2 related gene or the inflammatory factor comprises the following steps:

step 1, human primary skin keratinocytes were cultured in a medium containing 5% C0 at 37 ℃₂And culturing in an incubator at the temperature of 95 percent. After the cells are fused when the cells grow to more than 80%, plating. After further culturing for 72h, 5 test groups were set, respectively: normal group, IL-4/IL-13 induced group, powder grain complex single group, radix Ophiopogonis root extract single group, powder grain complex + radix Ophiopogonis root extract group, wherein the "normal group" is a control group without IL4/IL-13 and drug, the "IL 4/IL-13 induced group" is a model control group, and all experimental groups except the "normal group" are continuously stimulated with IL-4 and IL-13(15ng/ml) for 4 days.

And 2, sucking the supernatant obtained in the step 1, washing the supernatant once by using PBS, extracting RNA by using a Trizol method, reversing the RNA into cDNA, detecting the gene expression condition by using real-time fluorescence quantitative PCR, and relatively quantifying the expression quantity of the CAII gene and the NELL2 gene by using a 2-delta Ct method according to the obtained result. The results are shown in FIGS. 2 and 3, in which GAPDH is glyceraldehyde-3-phosphate dehydrogenase, which is one of housekeeping genes of cells and is commonly used as an internal reference gene in Q-PCR experiments, and the expression level of the target gene can be calibrated by the difference in CT values of the target gene and the internal reference gene. The primer information is as follows:

and 3, sucking the supernatant obtained in the step l, and detecting the amount of the IL-8 in the supernatant by an enzyme-linked immunosorbent assay (ELISA) method. The results are shown in FIG. 4.

And (3) analyzing an experimental result: as can be seen from FIG. 2, after the cells are stimulated and induced by IL-4/IL-13, the CAII gene expression is obviously up-regulated, and the gene expression of CAII can be obviously down-regulated when the tetrandrine compound (the compound of tetrandrine and beta-sitosterol) or the ophiopogon root extract is used alone; after the powder-grain compound and the radix ophiopogonis extract are combined and compatible, the inhibition effect is obviously better than that of the powder-grain compound or the radix ophiopogonis extract singly.

As can be seen from FIG. 3, after the cells are induced by IL-4/IL-13 stimulation, the gene expression of NELL2 is obviously up-regulated, and the gene expression of NELL2 can be obviously down-regulated when the powder-grain compound or the radix ophiopogonis extract is used alone. After the powder-grain compound and the radix ophiopogonis extract are combined and compatible, the inhibition effect is obviously better than that of the powder-grain compound or the radix ophiopogonis extract singly.

As can be seen from FIG. 4, after the cells are stimulated and induced by IL-4/IL-13, the expression of IL-8 is obviously increased, and the expression of IL-8 inflammatory factors can be obviously inhibited by using the powder-grain compound alone or the radix ophiopogonis extract alone. After the powder-grain compound and the radix ophiopogonis extract are used for compatibility, the inhibition effect can be synergistically enhanced, and the inhibition effect is superior to that of the powder-grain compound or the radix ophiopogonis extract singly.

In summary, the combination of the powder-grain compound and the radix ophiopogonis extract can achieve a good synergistic anti-allergy effect.

Example 2

The composite active matter of the embodiment comprises the following raw materials in parts by mass: 1 part of tetrandrine, 5 parts of beta-sitosterol and 8 parts of radix ophiopogonis extract. The preparation method of the ophiopogon root extract is the same as that of example 1.

Effect example 2

The composition prepared in example 2 was used to repeat steps 1 to 3 of effect example 1, and the results are shown in FIGS. 5 to 7.

And (3) analyzing an experimental result: as can be seen from FIG. 5, after the cells are stimulated and induced by IL-4/IL-13, the CAII gene expression is obviously up-regulated, and the powder-grain compound (the compound of tetrandrine and beta-sitosterol) can obviously down-regulate the CAII gene expression by singly using the powder-grain compound; the expression of CAII gene cannot be inhibited by using the radix ophiopogonis extract alone; after the powder-grain compound and the radix ophiopogonis extract are combined, the inhibition effect is obviously better than that of the powder-grain compound singly.

As can be seen from FIG. 6, after the cells are induced by IL-4/IL-13 stimulation, the gene expression of NELL2 is obviously up-regulated, and the gene expression of NELL2 can be obviously down-regulated when the powder-grain compound or the radix ophiopogonis extract is used alone. After the powder-grain compound and the radix ophiopogonis extract are combined, the inhibition effect is obviously better than that of the powder-grain compound or the radix ophiopogonis extract singly.

As can be seen from FIG. 7, after the cells are induced by IL-4/IL-13 stimulation, the expression of IL-8 is obviously increased, and the expression of IL-8 inflammatory factors can be obviously inhibited by using the powder-grain compound alone or the radix ophiopogonis extract alone. After the powder-grain compound and the radix ophiopogonis root extract are used for compatibility, the inhibition effect can be synergistically enhanced, and the inhibition effect is superior to that of the powder-grain compound or the radix ophiopogonis root extract singly.

Example 3

The composite active matter of the embodiment comprises the following raw materials in parts by mass: 5 parts of tetrandrine, 10 parts of beta-sitosterol and 12 parts of radix ophiopogonis extract. The preparation method of the ophiopogon root extract is the same as that of example 1.

Effect example 3

The composition prepared in example 3 was used to repeat steps 1 to 3 of effect example 1, and the results are shown in FIGS. 8 to 10.

And (3) analyzing an experimental result: as can be seen from FIG. 8, after the cells are stimulated and induced by IL-4/IL-13, the CAII gene expression is obviously up-regulated, and the powder grain compound alone can obviously down-regulate the CAII gene expression; the radix ophiopogonis extract can also inhibit the expression of CAII gene by being used alone, and shows good anti-allergy effect; after the powder-grain compound and the radix ophiopogonis extract are used for compatibility, the inhibition effect is obviously better than that of the powder-grain compound or the radix ophiopogonis extract used alone.

As can be seen in FIG. 9, NELL2 gene expression was significantly up-regulated after cells were induced by IL-4/IL-13 stimulation, and the pink grain complex alone could down-regulate NELL2 gene expression. The expression of NELL2 was also significantly inhibited after the radix Ophiopogonis extract alone was administered. After the powder-grain compound and the radix ophiopogonis extract are used for compatibility, the inhibition effect is obviously better than that of the powder-grain compound or the radix ophiopogonis extract used alone.

As can be seen from FIG. 10, after the cells are induced by IL-4/IL-13 stimulation, the expression of IL-8 is obviously increased, and the expression of IL-8 inflammatory factors can be obviously inhibited by using the powder-grain compound alone or the radix ophiopogonis extract alone. After the powder-grain compound and the radix ophiopogonis extract are used for compatibility, the inhibition effect can be synergistically enhanced, and the inhibition effect is superior to that of the powder-grain compound and the radix ophiopogonis extract singly.

Example 4

The preparation of the anti-allergy repair cream comprises the following steps:

wherein the active phase components comprise 1 part by mass of tetrandra root extract, 5 parts by mass of beta-sitosterol and 8 parts by mass of ophiopogon root extract;

the preparation method of the radix ophiopogonis extract comprises the following steps: pulverizing radix Ophiopogonis, mixing radix Ophiopogonis and water at a mass ratio of l to 8, heating to 90 deg.C, extracting for 3 hr, decolorizing with active carbon, and concentrating under reduced pressure to 0.4 volume to obtain radix Ophiopogonis extract.

Example 5

The preparation of the anti-allergy repair cream comprises the following steps:

wherein the active phase components comprise 3 parts by mass of tetrandra root extract, 8 parts by mass of beta-sitosterol and 10 parts by mass of ophiopogon root extract;

Example 6

The preparation of the anti-allergy repair cream comprises the following steps:

wherein the active phase components comprise 5 parts by mass of tetrandra root extract, 10 parts by mass of beta-sitosterol and 12 parts by mass of ophiopogon root extract;

Comparative example 1

wherein the oil phase component comprises 2-5% cetearyl olive oleate, 1-3% sorbitan olive oleate, 3-5% cyclopentadimethylsiloxane, 5-8% squalane, 1-2% lecithin, 0.05-1% hydrogenated lecithin, 1-3% cetearyl alcohol, 2-5% polydimethylsiloxane, 0.05-1% tocopherol, and 1-5% jojoba (SIMMONDSIA CHINENSIS) seed oil; wherein the water phase component comprises 3-8% of glycerin, 0.05-0.5% of carbomer, 0.5-2% of 1, 2-hexanediol, 0.5-5% of 1, 2-pentanediol, 1-5% of isoprene glycol, 0.05-0.2% of EDTA disodium, 0.5-5% of panthenol, 0.05-0.5% of menthol lactate, 0.02-0.2% of sodium hyaluronate and the balance of water;

wherein the active phase components comprise 1 part by mass of tetrandra root extract and 5 parts by mass of beta-sitosterol;

Comparative example 2

wherein the active phase component comprises 5 parts by mass of radix ophiopogonis extract;

Comparative example 3

step five: after the heat preservation time is up, cooling to 35 ℃;

step six: stirring for 10-30 min until the mixture is uniform and has no particles;

Effect example 4 skin TEWL value and Water content test

Experimental principles: the evaluation and inspection of the human body efficacy of the cosmetics are in accordance with the basic principle of the international declaration of helsinki, and the testee is required to sign an informed consent and take necessary medical protection measures, so that the benefits of the testee are protected to the maximum extent. The tested cosmetics are products which are qualified through microbiological indexes, harmful substance limit values and physicochemical indexes, toxicological tests and human body skin patch tests are completed before human body efficacy tests of the cosmetics, written proofs are provided, and human body efficacy tests are not performed on samples which are unqualified in the tests, wherein detection methods and qualified judgment standards of the toxicological tests and the human body skin patch tests are in accordance with corresponding file requirements issued by the state or an authority.

And (3) testing conditions are as follows: testing the environmental temperature: 20-22 ℃, relative humidity: 40-60% and real-time dynamic monitoring is carried out. The test conditions during the test should be consistent, such as: testers, sites, instruments, etc.

The subject claims: volunteers were selected as subjects who met the following conditions:

(1) ensure that the number of effective people is not less than 30.

(2) The subject was not selected as the one having the following condition

a. Those who have undergone cosmetic surgery such as chemical exfoliation, plastic remodeling, etc.;

b. those who use antihistamines for nearly one week or immunosuppressants for nearly one month;

c. in the last two months, any anti-inflammatory drug is applied to the tested part;

d. the subject has a clinically unvulcanized inflammatory skin condition;

e. insulin-dependent diabetic patients;

f. patients suffering from asthma or other chronic respiratory diseases undergoing therapy;

g. those receiving anti-cancer chemotherapy within approximately 6 months;

h. patients with immunodeficiency or autoimmune disease;

i. lactating or pregnant women;

j. bilateral mastectomy and bilateral underarm lymph node resection;

k. the judgment of the test result is influenced by scars, pigments, atrophy, port wine stains or other flaws on the skin to be tested;

participation in other clinical trial investigators;

m. those with high constitutional sensitivity;

non-volunteer participants or those who cannot complete the specified content according to the test requirements.

Requirements during the test: the tested part is forbidden to use the preparation which influences the moisturizing test. The subject is mainly in indoor activities and is prevented from being exposed to light for a long time.

Skin TEWL value and moisture content determination procedure:

(1) preparation before testing

The tested parts of all the subjects are unified into the forearm curve side of 2 multiplied by 2 cm; each test area is spaced by 2 cm; before the test of the areas, the 3M adhesive tape is required to be repeatedly torn and pulled to carry out cutin peeling treatment; simulating skin with damaged barrier.

No product (cosmetic or pharmaceutical) can be used 2-3 days before testing; prior to each test, subjects cleanse the test site and blot with an anti-dandruff absorbent paper towel. Sit still for 30min in a standard test environment, no water or beverage can be drunk, the forearm test area is exposed, and the forearm test area is kept relaxed, so that the tested part is prevented from being touched.

(2) The determination step comprises:

the inner side of the forearm of the arm is divided into eight areas: normal group, no exfoliation of keratin; blank group, no product is smeared after cutin stripping; the other six areas are subjected to cutin peeling according to the ratio of 2mg +/-0.1 mg sample/cm²The cosmetic compositions of examples 4 to 6 and comparative examples 1 to 3 were applied in amounts such that the sample to be tested was evenly spread on the test area using a latex finger-glove; after being applied uniformly, 3 hours after each day, the water dispersion loss (TEWL) in the tested area and the blank area was measured using a skin moisture loss tester, Tewameter TM300, and the water content was measured using a skin moisture content tester, Comeometer 825Coyrage, at the same time, and the average values of the water dispersion and water content of the skin of 30 subjects were calculated, respectively, for a test period of 28 days (i.e., the same test site was used for the same product every day, and the data after each day was collected for 28 days). The TEWL assay results are shown in Table 1 and FIG. 11; the results of the moisture content measurements are shown in table 2 and fig. 12.

TABLE 130 skin moisture loss (TEWL) mean values (units: g/hm) of the subjects²)

TABLE 230 mean skin moisture content of subjects (units: microsiesis per centimeter, μ s/cm)

And (4) analyzing results: as can be seen from tables 1-2 and FIGS. 11-12:

1. from the blank control and the trend of TEWL in examples 4-6, it can be seen that the blank control is not used with a repair product, the skin barrier repair is slow depending on the skin self-repair ability, and the anti-allergy repair cream of the present invention can accelerate the repair of damaged stratum corneum and increase the skin water content, thereby improving the skin barrier function.

2. From examples 4-6, it can be seen that the TEWL of the skin starts to decrease the next day after application of the product and the water content starts to gradually increase, indicating that the damaged skin barrier has started to repair. With respect to the water content, the water content of examples 4 to 6 was higher as a whole than that of comparative examples 1 to 3.

3. Comparative group 3 is a cosmetic base to which no effective ingredient is added, and the results show that there is no significant repairing effect on the skin barrier repair; the efficacy of the product is proved to be mainly achieved by the combination of the active substances in the invention.

It should be noted that the embodiments of the present invention have been described in terms of preferred embodiments, and not by way of limitation, and that those skilled in the art can make modifications and variations of the embodiments described above without departing from the spirit of the invention.

Claims

1. The cosmetic composition for anti-allergy restoration is characterized by comprising the following raw materials in parts by mass: 1-5 parts of tetrandrine, 5-10 parts of beta-sitosterol, 8-12 parts of radix ophiopogonis extract and auxiliary materials.

2. The cosmetic composition for anti-allergy restoration according to claim l, wherein the adjuvant is selected from any one or more of emulsifiers, thickeners, antioxidants, moisturizers, emollients, anti-inflammatory agents, solubilizers, chelating agents, fragrances, PH regulators, preservatives, penetration enhancers, skin-feel regulators, surfactants, pigments, propellants.

3. The cosmetic composition for anti-allergy restoration according to claim 1, wherein the adjuvant is selected from any one or more of cetearyl olivate, sorbitan olivate, cyclopentadimethylsiloxane, squalane, lecithin, hydrogenated lecithin, cetearyl alcohol, polydimethylsiloxane, tocopherol, jojoba seed oil, glycerin, carbomer, 1, 2-hexanediol, 1, 2-pentanediol, isoprene glycol, disodium EDTA, panthenol, menthol lactate, and sodium hyaluronate.

4. The cosmetic composition for anti-allergy restoration according to claim 3, characterized in that the content of cetearyl olive oleate is 2-5%, the content of sorbitan olive oleate is 1-3%, the content of cyclopentadimethylsiloxane is 3-5%, the content of squalane is 5-8%, the content of lecithin is 1-2%, the content of hydrogenated lecithin is 0.05-1%, the content of cetearyl alcohol is 1-3%, the content of polydimethylsiloxane is 2-5%, the content of tocopherol is 0.05-1%, the content of jojoba seed oil is 1-5%, the content of glycerol is 3-8%, the content of carbomer is 0.05-0.5%, the content of 1, 2-hexanediol is 0.5-2%, the content of 1, 2-pentanediol is 0.5-5%, the content of glycerol is 3-8%, 1-5% of isoprene glycol, 0.05-0.2% of EDTA disodium, 0.5-5% of panthenol, 0.05-0.5% of menthol lactate and 0.02-0.2% of sodium hyaluronate.

5. The cosmetic composition for anti-allergy restoration according to claim l, wherein the preparation method of the radix ophiopogonis extract comprises the steps of: pulverizing radix Ophiopogonis, mixing radix Ophiopogonis and water at a mass ratio of 1:8, heating to 80-100 deg.C, extracting for 2-4 hr, and concentrating under reduced pressure to 0.4 vol to obtain radix Ophiopogonis extract.

6. The cosmetic composition for anti-allergy restoration according to any one of claims l to 5, wherein the dosage form of the cosmetic composition is cream, lotion, gel, aerosol, or aqua.

7. The cosmetic composition for anti-allergy restoration according to any one of claims l to 5, wherein the cosmetic is selected from any one or more of facial mask, face cleansing cream, skin care water, skin care milk, skin care cream, skin care gel, skin care spray and foundation liquid.

8. A method for preparing a cosmetic composition for anti-allergy restoration, comprising the steps of:

step seven: detecting viscosity, density, PH, appearance and microorganisms;

the oil phase component comprises 2-5% of cetearyl olive oleate, 1-3% of sorbitan olive oleate, 3-5% of cyclopentadimethylsiloxane, 5-8% of squalane, 1-2% of lecithin, 0.05-1% of hydrogenated lecithin, 1-3% of cetearyl alcohol, 2-5% of polydimethylsiloxane, 0.05-1% of tocopherol, and 1-5% of jojoba seed oil;

the water phase component comprises 3-8% of glycerin, 0.05-0.5% of carbomer, 0.5-2% of 1, 2-hexanediol, 0.5-5% of 1, 2-pentanediol, 1-5% of isoprene glycol, 0.05-0.2% of EDTA disodium, 0.5-5% of panthenol, 0.05-0.5% of menthol lactate, 0.02-0.2% of sodium hyaluronate and the balance of water;

the active phase component comprises 0.0001-0.0005% of radix Stephaniae Japonicae extract, 0.0005-0.001% of beta-sitosterol, and 0.0008-0.0012% of radix Ophiopogonis extract.